Rounds with the Investigators 2012 | Lung

QUESTION: I would like to know from the lung cancer investigators what is the incidence of EGFR or EML4-ALK mutations if a tumor tests positive for K-ras mutation. I have a patient who was diagnosed in 2010 and tested positive for K-ras mutation and negative for EGFR mutation. EML4-ALK testing was not performed at that time, and there is insufficient material to perform the testing from the original specimen. She has now recurred, and I wonder if there is a high enough probability of EML4-ALK mutation to perform a repeat biopsy.

DR NEIL LOVE: Steve, can you kind of present the case that was behind your question?

Rounds with the Investigators 2012 | Lung

QUESTION: My second case is a 67 y/o F with an incidental finding of an RUL mass on CXR with enlargement on CT at a 3-month follow-up scan. PET only slightly hypermetabolic. Bronch showed question of bronchoalveolar carcinoma. She underwent RUL resection and was found to have a 3.0-cm adenocarcinoma with some areas of poorly differentiated disease and areas of lymphovascular invasion. Three out of 6 peribronchial LNs were positive. She was EGFR positive. What is the “preferred” adjuvant regimen for this patient? I have treated her with cisplatin and vinorelbine, and it has been relatively poorly tolerated. Is there any role for adjuvant erlotinib?

Rounds with the Investigators 2012 | Lung

QUESTION: My case is a 58 y/o F with limited small cell lung cancer, mediastinal LN involvement at dx with tumor invasion of the SVC and a very large R supraclavicular mass. Tx with carbo/VP16 and RT with CR and followed by PCI. At first follow-up CT at 3 months pt was found to have no disease recurrence in chest but a mass in the transverse colon. Colonoscopy with biopsy showed recurrent small cell lung cancer. For limited small cell lung cancer is cisplatin superior to carboplatin? Should this patient have received cisplatin?

Rounds with the Investigators 2012 | Lung

Disclosures:

Patterns of Care in Breast Cancer — Interactive Edition: Adjuvant chemotherapy for ER-positive, HER2-negative tumors